安德森-塔维尔综合征1型的自然病史与风险分层
该研究纳入来自57个家系的118例安德森-塔维尔综合征1型(ATS1)患者,中位随访6.2年,发现5年累积危及生命心律失常事件(LAE)概率为7.9%;晕厥史、持续性室速记录及胺碘酮使用与LAE风险升高相关,而β受体阻滞剂单用或联用Ic类抗心律失常药未降低LAE发生率。
要点
- ATS1患者LAE风险较高,5年累积概率7.9%。
- 不明原因晕厥或记录到持续性室速提示LAE高风险。
- 胺碘酮具致心律失常作用,ATS1患者应避免使用。
核心结论
- ATS1临床病程以高LAE发生率为特征,晕厥史或持续性室速史与LAE风险升高相关,胺碘酮应避免使用。
研究设计与样本
- 多中心回顾性队列研究,纳入23个中心连续ATS1患者共118例(来自57个家系),入组年龄23±17岁。
主要发现
- 中位随访6.2年(四分位距2.7至16.5年),17例患者发生首次LAE,5年累积概率7.9%。
- LAE风险升高与晕厥史(HR 4.54;p=0.02)、持续性室速记录(HR 9.34;p=0.001)及胺碘酮使用(HR 268;p<0.001)相关。
- 无治疗时LAE发生率为1.24/100人年,β受体阻滞剂单用(1.37/100人年;p=1.00)或联用Ic类抗心律失常药(1.46/100人年;p=1.00)均未降低该发生率。
关键数值与推荐
- 晕厥史:HR 4.54(p=0.02);持续性室速记录:HR 9.34(p=0.001);胺碘酮使用:HR 268(p<0.001)。
- 无治疗LAE率1.24/100人年;β受体阻滞剂单用1.37/100人年(p=1.00);联用Ic类1.46/100人年(p=1.00)。
临床怎么用
- 对ATS1患者应评估晕厥史和持续性室速记录以进行风险分层。
- 避免使用胺碘酮,因其与LAE风险显著升高相关。
- β受体阻滞剂单用或联用Ic类抗心律失常药未显示降低LAE,需探索其他治疗策略。
局限性
- 回顾性多中心队列设计可能存在选择偏倚和信息偏倚。
- 胺碘酮相关HR 268基于极小样本事件数,估计值不稳定。
- 未报告除β受体阻滞剂和Ic类外其他抗心律失常治疗的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Andersen-Tawil Syndrome type 1 (ATS1) is a rare arrhythmogenic disorder, caused by loss-of-function mutations in the KCNJ2 gene. We present here the largest cohort of patients with ATS1 with outcome data reported. OBJECTIVES: This study sought to define the risk of life-threatening arrhythmic events (LAE), identify predictors of such events, and define the efficacy of antiarrhythmic therapy in patients with ATS1. METHODS: Clinical and genetic data from consecutive patients with ATS1 from 23 centers were entered in a database implemented at ICS Maugeri in Pavia, Italy, and pooled for analysis. RESULTS: We enrolled 118 patients with ATS1 from 57 families (age 23 ± 17 years at enrollment). Over a median follow-up of 6.2 years (interquartile range: 2.7 to 16.5 years), 17 patients experienced a first LAE, with a cumulative probability of 7.9% at 5 years. An increased risk of LAE was associated with a history of syncope (hazard ratio [HR]: 4.54; p = 0.02), with the documentation of sustained ventricular tachycardia (HR 9.34; p = 0.001) and with the administration of amiodarone (HR: 268; p < 0.001). The rate of LAE without therapy (1.24 per 100 person-years [py]) was not reduced by beta-blockers alone (1.37 per 100 py; p = 1.00), or in combination with Class Ic antiarrhythmic drugs (1.46 per 100 py, p = 1.00). CONCLUSIONS: Our data demonstrate that the clinical course of patients with ATS1 is characterized by a high rate of LAE. A history of unexplained syncope or of documented sustained ventricular tachycardia is associated with a higher risk of LAE. Amiodarone is proarrhythmic and should be avoided in patients with ATS1.
引用
- Mazzanti A, Guz D, Trancuccio A, et al. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. J Am Coll Cardiol. 2020. PMID: 32299589. doi:10.1016/j.jacc.2020.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。